| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J9025 | Azacitidine | Vidaza | 1 mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | No | 2004 | Jan 1, 2006 | In Use | ||
| NA | Diethylstilbestrol | DES, Stilbestrol | unspecified | Hormonal Therapy | Estrogen | No | 1905 | 2000 | In Use | |||
| NA | Axitinib | Axitinib | 5 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Yes | 2012 | In Use | |||
| J9172 | Docetaxel (Ingenus) | Docetaxel | 1mg | Chemotherapy | Antimitotic Agent | Taxane | No | 2017 | Dec 7, 2023 | In Use | ||
| J9041 | Bortezomib | Velcade | 0.1 mg | Chemotherapy | Proteasome Inhibitor | 26S | No | 2003 | Jan 1, 2005 | In Use | ||
| J1094 | Dexamethasone Acetate | Dalalone DP, Decadron-LA | 1 mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | No | 1978 | 2014 | Jan 1, 2003 | In Use | |
| NA | Elacestrant | Orserdu | Multiple | Hormonal Therapy | Estrogen Receptor Antagonist | ERÉ‘ | Yes | 2023 | In Use | |||
| J9100 | Cytarabine | Cytarabine | 100 mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | No | 1998 | Jan 1, 1986 | In Use | ||
| NA | Dabrafenib | Tafinlar | 75 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BRAF | Yes | 2013 | Jan 1, 2004 | In Use | ||
| NA | Crizotinib | Xalkori | 200 mg | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Yes | 2011 | In Use | |||
| NA | Estramustine Phosphate Sodium | Emcyt | 140 mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Yes | 1981 | In Use | |||
| NA | Entrectinib | Rozlytrek | 100mg, 200mg | Chemotherapy | Tyrosine Kinase Inhibitor | TRKA, TRKB, TRKC, ROS1, ALK | Yes | 2019 | In Use | |||
| Q5165 | Denosumab-mobz | Oziltus | 1mg | Ancillary Therapy | Monoclonal Antibody | RANKL | No | 2025 | Jun 17, 2026 | In Use | ||
| J9015 | Aldesleukin | Proleukin | Per single vial (1 vial = 22 million IU) | Immunotherapy | Cytokine | Interleukin-2 | No | 1992 | Oct 1, 1996 | In Use | ||
| Fruquintinib | Fruzaqla | 1mg, 5mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Yes | 2023 | In Use | ||||
| NA | Cabozantinib | Cometriq | 20 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Yes | 2012 | In Use | |||
| J3300 | Triamcinolone | Kenalog, Aristocort | 1 mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | No | 1960 | Jan 1, 2009 | In Use | ||
| J9179 | Eribulin mesylate | Halaven | 0.1 mg | Chemotherapy | Antimitotic Agent | Furopyrans | No | 2010 | Jan 1, 2012 | In Use | ||
| NA | Diethylstilbestrol | DES, Stilbestrol | unspecified | Hormonal Therapy | Estrogen | Yes | 1905 | 2000 | In Use | |||
| NA | Erlotinib | Tarceva | 100 mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2004 | In Use | |||
| J9304 | Pemetrexed | Pemfexy | 10mg | Chemotherapy | Antimetabolite | Folic Acid Analog | No | 2020 | Oct 1, 2020 | In Use | ||
| C9066 | Sacituzumab govitecan-hziy | Trodelvy | 10mg | Immunotherapy | Drug Antibody Conjugate | Trop-2 | No | 2020 | Oct 1, 2020 | Jan 1, 2021 | In Use | |
| J8530 | Cyclophosphamide | Cyclophosphamide oral | 25 mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Yes | 1959 | Jan 1, 1995 | In Use | ||
| S0176 | Hydroxyurea | Hydrea | 500 mg | Chemotherapy | Miscellaneous Agent | Antimetabolite/Organooxygen | Yes | 1967 | Jan 1, 2002 | In Use | ||
| NA | Cysteamine Bitartrate | Procysbi | 25mg, 75mg, 300mg | Chemotherapy | Cystine-Depleting Agent | Yes | 2013 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home